Clinical Trial: Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07368270) titled 'Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma' on Jan. 18.

Brief Summary: The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Intervention: BIOLOGICAL: Anti-PD1 armored CD19 CAR-T cells

Anti-PD1 armored CD19 CAR-T cells, single intravenous infusion

Recruitment Status: RECR...